(Q43297447)

18 November 2017

title

Topical resiquimod promotes priming of CTL to parenteral antigens (English)

1 reference

18 November 2017

Brent A Chang

1

1 reference

18 November 2017

Jennifer L Cross

series ordinal

2

1 reference

18 November 2017

Hossain M Najar

series ordinal

3

1 reference

18 November 2017

Jan P Dutz

series ordinal

4

1 reference

18 November 2017

language of work or name

English

0 references

publication date

4 August 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

27

1 reference

18 November 2017

issue

42

1 reference

18 November 2017

page(s)

5791-5799

1 reference

Exploiting dendritic cells to improve vaccine efficacy

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Dendritic cells: translating innate to adaptive immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Resiquimod and other immune response modifiers as vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Type I interferon dependence of plasmacytoid dendritic cell activation and migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Cytokine induction by the immunomodulators imiquimod and S-27609

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Tumours can act as adjuvants for humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Quantification of antigen specific CD8+ T cells using an ELISPOT assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Expression of MxA protein in inflammatory dermatoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

The human intracellular Mx-homologous protein is specifically induced by type I interferons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.062

10.1016/J.VACCINE.2009.07.062

7 January 2021

Identifiers

DOI

1 reference

18 November 2017

1 reference